Ocular Therapeutix™ to Present at Two Upcoming Investor Conferences
May 06 2024 - 7:30AM
Ocular Therapeutix, Inc. (NASDAQ:OCUL, “Ocular”, the “Company”), a
biopharmaceutical company committed to enhancing people’s vision
and quality of life through the development and commercialization
of innovative therapies for wet age-related macular degeneration
(wet AMD), diabetic retinopathy, and other diseases and conditions
of the eye, today announced that it will participate at two
investor conferences in May:
Citizens JMP Life Sciences Conference Fireside
Chat Date: Monday, May 13, 2024 Fireside Chat Time: 1:00 PM ET
Location: New York, NY
BofA Securities 2024 Health Care Conference
Fireside Chat Date: Wednesday, May 15, 2024 Fireside Chat Time:
3:00 PM PTLocation: Las Vegas, NV
A live webcast of the fireside chats at the Citizens JMP Life
Sciences Conference and BofA Securities 2024 Health Care Conference
can be accessed by visiting the Investors section of the Company’s
website at investors.ocutx.com.
About Ocular
Therapeutix, Inc.Ocular
Therapeutix, Inc. is a biopharmaceutical company committed to
enhancing people’s vision and quality of life through the
development and commercialization of innovative therapies for wet
age-related macular degeneration (wet AMD), diabetic retinopathy
(DR), and other diseases and conditions of the
eye. AXPAXLI™ (axitinib intravitreal implant, also known
as OTX-TKI), Ocular’s product candidate for retinal disease, is
based on its ELUTYX™ proprietary bioresorbable hydrogel-based
formulation technology. AXPAXLI is currently in a Phase 3 clinical
trial for wet AMD. The clinical portfolio also
includes PAXTRAVA™ (travoprost intracameral implant, also
known as OTX-TIC), currently in a Phase 2 clinical trial for the
treatment of open-angle glaucoma or ocular hypertension.
Ocular’s expertise in the formulation, development and
commercialization of innovative therapies of the eye and the ELUTYX
platform supported the development and launch of its first
commercial drug product, DEXTENZA®, an FDA-approved
corticosteroid for the treatment of ocular inflammation and pain
following ophthalmic surgery and ocular itching associated with
allergic conjunctivitis. ELUTYX is also the foundation for two
other clinical-stage assets, OTX-CSI (cyclosporine
intracanalicular insert) for the chronic treatment of dry eye
disease and OTX-DED (dexamethasone intracanalicular
insert) for the short-term treatment of the signs and symptoms of
dry eye disease, as well as several preclinical programs.
Follow us on our website, LinkedIn or X.
Investors & MediaOcular Therapeutix,
Inc.Bill SlatteryVice President, Investor
Relationsbslattery@ocutx.com
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Ocular Therapeutix (NASDAQ:OCUL)
Historical Stock Chart
From Oct 2023 to Oct 2024